217 related articles for article (PubMed ID: 37295608)
21. Neovascular age-related macular degeneration treated with ranibizumab or aflibercept in the same large clinical setting: visual outcome and number of injections.
Rasmussen A; Sander B; Larsen M; Brandi S; Fuchs J; Hansen LH; Lund-Andersen H
Acta Ophthalmol; 2017 Mar; 95(2):128-132. PubMed ID: 27535819
[TBL] [Abstract][Full Text] [Related]
22. The Influence of COVID-19 on the Stability of Patients with Neovascular Age-Related Macular Degeneration with Different Treatment Regimens.
Jiang B; Gao L; Dong S; Hou Q; Sun M; Zhang J; Yu H; Zhang Z; Sun D
Adv Ther; 2022 Apr; 39(4):1568-1581. PubMed ID: 34817809
[TBL] [Abstract][Full Text] [Related]
23. Comparison of visual outcomes of polypoidal choroidal vasculopathy and typical neovascular age-related macular degeneration-up to 10 years of follow-up.
Park JY; Park YJ; Park SJ; Park KH; Yeo JH; Kim JG; Yoon YH; Lee JY; Woo SJ
Acta Ophthalmol; 2022 Dec; 100(8):e1579-e1588. PubMed ID: 35363434
[TBL] [Abstract][Full Text] [Related]
24. Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study.
Hatz K; Prünte C
Acta Ophthalmol; 2017 Feb; 95(1):e67-e72. PubMed ID: 27009503
[TBL] [Abstract][Full Text] [Related]
25. Seven-year outcome after 1-year fixed regimen of intravitreal aflibercept injections followed by pro re nata treatment for neovascular age-related macular degeneration.
Hama Y; Miyata M; Ooto S; Tamura H; Ueda-Arakawa N; Muraoka Y; Miyake M; Takahashi A; Wakazono T; Uji A; Yamashiro K; Tsujikawa A
Graefes Arch Clin Exp Ophthalmol; 2023 Jul; 261(7):1871-1881. PubMed ID: 36735070
[TBL] [Abstract][Full Text] [Related]
26. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
[TBL] [Abstract][Full Text] [Related]
27. Subtype prevalence and baseline visual acuity by age in Japanese patients with neovascular age-related macular degeneration.
Sawada T; Yasukawa T; Imaizumi H; Matsubara H; Kimura K; Terasaki H; Ishikawa H; Murakami T; Takeuchi M; Mitamura Y; Mizusawa Y; Takamura Y; Murata T; Kogo J; Ohji M
Jpn J Ophthalmol; 2023 Mar; 67(2):149-155. PubMed ID: 36879074
[TBL] [Abstract][Full Text] [Related]
28. Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration in Vulnerable Fellow Eyes: A Randomized Clinical Trial.
Chan CK; Lalezary M; Abraham P; Elman M; Beaulieu WT; Lin SG; Khurana RN; Bansal AS; Wieland MR; Palmer JD; Chang LK; Lujan BJ; Yiu G;
Ophthalmol Retina; 2022 Jun; 6(6):484-494. PubMed ID: 35121216
[TBL] [Abstract][Full Text] [Related]
29. Different Outcomes of Anti-VEGF Treatment for Neovascular AMD according to Neovascular Sutypes and Baseline Features: 2-Year Real-Life Clinical Outcomes.
Arrigo A; Saladino A; Aragona E; Mercuri S; Introini U; Bandello F; Parodi MB
Biomed Res Int; 2021; 2021():5516981. PubMed ID: 34124243
[TBL] [Abstract][Full Text] [Related]
30. Using optical coherence tomography angiography in assessment of the anti-vascular endothelial growth factor effect for pathological vascular tissue in age-related macular degeneration and polypoidal choroidal vasculopathy.
Shen YS; Cheng CK
Eur J Ophthalmol; 2021 May; 31(3):1267-1280. PubMed ID: 32228025
[TBL] [Abstract][Full Text] [Related]
31. Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study.
Augsburger M; Sarra GM; Imesch P
Graefes Arch Clin Exp Ophthalmol; 2019 Sep; 257(9):1889-1895. PubMed ID: 31256237
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy.
Ogasawara M; Koizumi H; Yamamoto A; Itagaki K; Saito M; Maruko I; Okada AA; Iida T; Sekiryu T
Jpn J Ophthalmol; 2018 Sep; 62(5):584-591. PubMed ID: 29974277
[TBL] [Abstract][Full Text] [Related]
33. Treat-and-Extend Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration: Efficacy and Macular Atrophy Development.
Matsumoto H; Morimoto M; Mimura K; Ito A; Akiyama H
Ophthalmol Retina; 2018 May; 2(5):462-468. PubMed ID: 31047326
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
Jin KW; Kim JH; Park JY; Park SJ; Park KH; Lee JY; Woo SJ
Sci Rep; 2021 Jul; 11(1):14623. PubMed ID: 34272419
[TBL] [Abstract][Full Text] [Related]
35. Impact of intravitreal ranibizumab, aflibercept and bevacizumab on retinal ganglion cell and nerve fibre layer thickness in Neovascular age-related macular degeneration.
Abu Dail Y; Seitz B; Sideroudi H; Abdin AD
Acta Ophthalmol; 2023 May; 101(3):330-341. PubMed ID: 36345883
[TBL] [Abstract][Full Text] [Related]
36. Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injection for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy.
Kitagawa Y; Shimada H; Mori R; Tanaka K; Yuzawa M
Ophthalmology; 2016 Jun; 123(6):1278-86. PubMed ID: 26949121
[TBL] [Abstract][Full Text] [Related]
37. CLINICAL OUTCOMES OF DIFFERENT SUBTYPES OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DURING AFLIBERCEPT TREATMENT.
Rezar-Dreindl S; Eibenberger K; Buehl W; Maccora K; Waldstein S; Baratsits M; Schmidt-Erfurth U; Sacu S
Retina; 2021 Jan; 41(1):103-110. PubMed ID: 32091488
[TBL] [Abstract][Full Text] [Related]
38. Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy.
Huang CH; Lai TT; Yang CH; Hsieh YT
Ophthalmol Ther; 2024 Jan; 13(1):385-396. PubMed ID: 37995014
[TBL] [Abstract][Full Text] [Related]
39. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.
Schmidt-Erfurth U; Waldstein SM; Deak GG; Kundi M; Simader C
Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255
[TBL] [Abstract][Full Text] [Related]
40. Timing of Complete Polypoidal Regression after Intravitreous Aflibercept Treatments in Polypoidal Choroidal Vasculopathy.
Chaikitmongkol V; Upaphong P; Patikulsila D; Jirarattanasopa P; Choovuthayakorn J; Watanachai N; Kunavisarut P; Ratanasukon M; Bhurayanontachai P; Ingviya T; Bressler SB; Bressler NM
Ophthalmol Retina; 2022 Jan; 6(1):21-28. PubMed ID: 33781929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
